Floatz logo

Tinengotinib

Intrahepatic Cholangiocarcinoma (Icc)

TransThera Sciences (Nanjing), Inc.Small moleculePhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

38 Active assets in the Intrahepatic Cholangiocarcinoma (Icc) cohort.

Asset / SponsorPhaseRating
Nivolumab
Virogin Biotech Canada Ltd
Phase 2BB
Durvalumab
West China Hospital
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Shanghai 6th People's Hospital
Phase 2BB
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 3B
Atezolizumab
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Tinengotinib is also rated in:

cholangiocarcinomaDormant
B
Indicative ·
59 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →
cancerDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →